one reviewer screened conference abstracts. We conducted calibration exercises to ensure consistency among reviewers. We retrieved the full texts of articles judged as potentially eligible by at least one reviewer. Two reviewers then independently screened all full texts for eligibility using a standardized form with explicit inclusion and exclusion criteria. Reviewers resolved their disagreements by discussion or by consulting a third reviewer (G. H. G.).
Data Abstraction
In pairs, reviewers independently abstracted the following data from each article using a standardized data abstraction form: study design; population and health conditions of interest; antithrombotic medication; outcomes assessed; results; and methodologic characteristics of the study, including systematic biases and potential limitations.
Data Analysis
We planned to conduct a meta-analysis if the treatment outcomes considered were comparable. The variability in methods and the ways outcomes were measured and presented made the generation of pooled estimates impossible. We present the results in narrative and tabular form, stratifi ed by the health condition.
Results

Included Studies
Of 48 studies selected for inclusion, 16 focused on patients with atrial fi brillation, [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] fi ve on patients with VTE, [19] [20] [21] [22] [23] four on stroke or myocardial infarction prophylaxis, [24] [25] [26] [27] six on thrombolysis in acute stroke or myocardial infarction, [28] [29] [30] [31] [32] [33] and 17 on the burden of antithrombotic treatment. [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] Strategies used to elicit patient preferences include visual analog scales 25, 37, 42, 50 ; standard gamble 17, 22, 23, 30 ; time trade-off [6] [7] [8] 15, [19] [20] [21] ; probability trade-off technique 3, 4, 9, 12, 25, 26 ; decision aids 10, 13, 14, 18, 31 ; the presentation of hypothetical scenarios in which participants are asked to make a treatment decision 5, 11, 16, 24, 32, 33 ; and methods used to elicit information about treatment burden, such as interviews and surveys. 27, 29, [35] [36] [37] [38] [39] [40] [41] [43] [44] [45] [46] [47] [48] [49] [50] Of the 48 included studies, 12 provided health state utilities or health state valuations obtained from participants with regard to both long-term and shortterm outcomes related to thrombolysis and prophylaxis treatments [6] [7] [8] 15, 17, [19] [20] [21] [22] [23] 25, 30 ( Table 1 ) . Health state utilities typically are assessed on a scale of 0 to 1, with 0 being equivalent or worse health, and 1 being optimal health. A patient or participant's utility value refl ects his or her opinions or attitudes toward a given health state or outcome. Disutility refers to the burden or negative outcomes associated with a particular health state.
Overall Findings
Although there were exceptions, 13, 14 participants across the studies tended to place a higher disutility on stroke than GI bleed 3, 4, 25 and much greater disutility
• Studies that examined patient preferences for antithrombotic therapy vs no or alternative antithrombotic therapy, which includes receiving both treatment for thromboembolic disease and prophylaxis as defi ned previously • Studies that examined in the context of consideration of antithrombotic therapy how patients value alternative health states and experiences with treatment • Studies that examined choices patients make when presented with decision aids for management options regarding antithrombotic therapy
We excluded studies of proxy decision makers and health-care professionals and studies that were not available in English.
Search Strategy
We developed electronic search strategies with the help of a health-care librarian (N. B.). We searched Medline, Embase, Psychinfo, HealthStar, CINAHL, CENTRAL, and International Pharmaceuticals Abstracts between August and September 2009, starting with the dates of inception of each database.
We also searched the gray literature, including the International Society for Quality of Life conference abstracts (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) , the Society for Medical Decision Making conference abstracts available online (2001, (2004) (2005) (2006) (2007) (2008) , PapersFirst, and Dissertations and Theses International. Finally, we reviewed reference lists of all eligible studies.
Selection of Studies
Two reviewers independently screened for eligibility the titles and abstracts of identifi ed articles. S. MacLean served as the fi rst reviewer, whereas six authors split the task of the second reviewer (S. McLeod, S. Mulla, M. J., E. A. A., P. O. V., and S. E.); only on stroke than treatment burden. [6] [7] [8] However, there was little consistency in health state utilities and preferences for treatment choices both within and across studies. We outline the range of participant preferences in categories of presentation. Unless otherwise indicated, the term "stroke" refers to the net of nonfatal hemorrhagic and nonfatal thrombotic stroke. The term "bleed" refers to nonfatal GI bleeding.
Atrial Fibrillation
Summary of Findings
Three studies reported compelling fi ndings of a higher disutility associated with stroke than with bleed. Alonso-Coello et al 3 found that 19 of 96 participants (20%) were willing to accept . 35 additional bleeds on warfarin for 3% absolute risk reduction of stroke. For this 20%, the disutility associated with one stroke was equal to the disutility associated with 11.6 bleeding episodes. The median threshold that patientparticipants were willing to accept was 10 bleeds for a 3% reduction in stroke (range, 1-100). Similarly, Devereaux and colleagues 4 found that 57% of participants were willing to accept 22 additional bleeds to achieve a stroke reduction of 8% (disutility of one stroke equal to 2.8 bleeds). The remaining 43% of participants varied considerably in the number of additional instances of bleed that they were willing to accept. The mean number of bleeds that all participants were willing to accept to achieve this 8% stroke reduction was 17.4.
Man-Son-Hing 12 found that given a bleeding risk of 3% over 2 years, the mean stroke reduction that participants required to accept warfarin was 1.65% over the same time period. Fifty-two percent of participants would accept warfarin for an absolute decrease in stroke risk by 1% over 2 years. The low treatment threshold in this study may be partly due to the fact that 90% of participants had been taking warfarin at the time of the fi rst interview, and all participants had previously been prescribed warfarin.
A number of studies reported a stroke-to-bleed preference ratio of , 2. 11, 13, 14 Patients enrolled in these studies appeared to place a considerably higher value on avoiding bleeding relative to avoiding stroke than did patients in most other studies. 13 Another study conducted by Man-Son-Hing and colleagues 14 randomized 199 participants to a qualitative vs quantitative version of a decision aid trial. None of the participants had atrial fi brillation, 31% had experienced aspirin treatment, and 6% had experienced warfarin treatment. The investigators categorized participants in both groups as low risk or moderate risk for stroke. In the low-risk group, or intracranial bleed. These omissions make the results diffi cult to interpret. To the extent, however, that patients assumed that the functional consequences of a thrombotic stroke and an intracranial bleed are similar, the results of this study suggest that many patients place a higher value on avoiding an adverse event that occurs as a consequence of treatment vs avoiding an event with the same functional consequences that occurs as a consequence of not using that treatment. Table 2 51-54 provides a summary of all studies that considered atrial fi brillation.
VTE/DVT Therapy
Summary of Findings
These studies illustrate signifi cant variability in elicited patient values and preferences regarding thrombosis prophylaxis and treatment. Locadia et al 20 described extremely large between-patient variability with regard to participant willingness to accept warfarin treatment at varying thresholds of recurrent DVT. In another study by Locadia et al, 21 the authors concluded that preferences stated in the form of health state utilities varied signifi cantly across the three methods ( Table 3 ) .
VTE/DVT Thrombolysis
Summary of Findings
A study by O'Meara et al 23 found that no participant values and preferences were consistent with taking streptokinase, which differs from the fi ndings of Lenert and Soetikno 22 where the majority of participant preferences were consistent with use of streptokinase. Lenert and Soetikno 22 explained these differences in results by arguing that their participants were better educated about the risks and benefi ts of DVT and its treatment, given that participants were presented with video and audio descriptions. O'Meara et al 23 provided only written material to participants; thus, their participants may have lacked a full understanding of the outcomes associated with antithrombotic treatment. Another factor potentially affecting results is that participants in the Lenert and Soetikno 22 study were younger and, thus, potentially less risk averse than the participants in the O'Meara et al 23 
The results of each of these studies illustrate how design features and participant characteristics may participants were told that warfarin, compared with aspirin, resulted in a 1% reduction in stroke and a 2.5% increase in bleeds. The majority (69%) of participants in this group chose aspirin; 4% chose warfarin, 14% chose no medication, and 13% were unable to make a treatment decision. The majority who chose aspirin placed an implicit value on stroke reduction of , 2.5 times the disutility of bleeding.
In the moderate-risk group, participants were told that warfarin, compared with aspirin, results in a 3% absolute risk reduction in stroke and a 2.5% increase in bleeds. The majority (58.1%) of participants in this group chose aspirin; 11% opted for no treatment, 12% chose warfarin, and 18.4% were unable to make a treatment decision. The majority who chose aspirin placed a value on stroke reduction of , 0.83 times the value placed on bleeding.
Holbrook and colleagues 11 presented participants with information about atrial fi brillation using an audiotape and booklet. In a typical scenario, warfarin provided a 6% absolute risk reduction in stroke (9%-3%) and a 4% absolute risk increase in bleed (2%-6%) compared with no treatment. In this scenario, 65% of participants chose warfarin, and 35% chose no treatment. For the 65% choosing warfarin, the disutility associated with one stroke was at least 1.5 times greater than the disutility associated with a major bleed.
There are several potential explanations for the variability in results among studies. The fi rst concerns participants' previous experience with antithrombotic treatment. The low treatment threshold in the 1996 study by Man-Son-Hing 12 ( . 50% had a disutility of stroke vs bleeding . 3:1) may be partly due to the fact that 90% of the participants had been taking warfarin at the time of the fi rst interview and that all participants had previously been prescribed warfarin. In contrast, participants in the 1999 study by ManSon-Hing et al 13 reported a higher disutility with bleeds. The patients in this study had chosen at enrollment in Stroke Prevention in Atrial Fibrillation III (SPAF) 2 years earlier to receive aspirin prophylaxis alone. Most, if not all, of the participants had not experienced a stroke during the subsequent 2 years. Participants may have believed that whatever the general risk of stroke while taking aspirin, their personal risk was lower (and, at least to some extent, they might have been correct in this deduction) 51 ( Table 2 ) .
Some studies do not provide enough information to enable us to make reliable inferences regarding patient preferences. For example, Fuller et al 5 did not report what information they provided patients about the mortality associated with stroke and bleed (presumably, their scenarios referred to nonfatal stroke and bleed), nor did they indicate whether they provided any information about the consequences of a thrombotic stroke Major bleed Of those patients who were randomized to receive the decision aid, 53% to 80% correctly estimated their risks of stroke and bleeding; in the control group, 16% to 28% were able to do so. Thus, the decision aid group more reliably refl ects underlying patient values in that patients were substantially more likely to understand the risks and benefi ts of the alternatives. Therefore, we focus on the results in patients who received the decision aid.
The 58 patients with hypertension were told that warfarin would reduce stroke risk by 4% relative to aspirin (from 8%-4%) over a period of 2 y. Because fi ve of the eight strokes in patients taking aspirin were minor, the reduction in major stroke would be from 3% to 1.5%. Warfarin would increase the risk of serious bleeding from 1% to 3%. Of these patients, 88% chose to continue taking aspirin. Thus, most patients placed an implicit value on avoiding stroke of, at most, one-half of what they placed on avoiding a bleed. In terms of major stroke, one stroke was associated with the disutility of at least 1.3 bleeds. Participants with hypertension were told that warfarin increases risk of serious bleeding from 1% to 3%. Of these patients, 95% chose to continue taking aspirin. Thus, almost all patients placed an implicit value on avoiding stroke of, at most, as great as the value they placed on avoiding a bleed. In terms of major stroke, one stroke was associated with the disutility of at least 2.6 bleeds. Patients who had been taking warfarin prior to enrolling in the SPAF III cohort study were approximately twice as likely to choose warfarin than those who had not taken warfarin prior to SPAF III. ment-induced adverse (eg, hemorrhagic stroke) events than avoiding events prevented as a result of treatment. This latter interpretation is consistent with results from Fuller et al, 5 who examined the relative aversion to thrombotic and hemorrhagic stroke and found that patients placed a greater value on avoiding treatment-induced strokes than on avoiding strokes that treatment could prevent. This fi nding could relate to the concept of loss aversion. 55 Stanek et al 32 suggested, in contrast with Heyland et al, 31 that participants were most concerned with mortality as opposed to stroke. Participants were most often unwilling to accept a higher risk of death in exchange for a reduction in stroke risk. Differences in results may be attributed to participant populations, methods, and outcomes considered. For example, Stanek et al 32 used a self-administered questionnaire, whereas Heyland et al 31 conducted a faceto-face preference elicitation exercise, with a research assistant guiding participants through the decision aid. Given that in Stanek, under conditions of no cost and 0% risk of mortality, approximately one-third of participants chose tissue plasminogen activator (which is associated with higher stroke risk), it is possible that at least some of these participants lacked a proper understanding of the risks and outcomes associated with each treatment. Heyland elicited preferences from participants considered at risk for myocardial infarction, whereas Stanek surveyed inpatients undergoing diagnostic coronary angiography. Finally, Stanek considered only hemorrhagic stroke, whereas Heyland included both hemorrhagic stroke and myocardial infarction ( Table 7 ).
Treatment Burden and Quality of Life
Summary of Findings
Warfarin is, for most patients, associated with relatively limited impact on quality of life and the ability to carry out daily activities. Although some patients report anxiety or worry over the risks that they incur while taking warfarin therapy, [35] [36] [37] 40, 41 they generally are satisfi ed with this treatment. 39, 46 Other elements of burden that patients report include dietary modifications and the inconvenience associated with frequent blood monitoring. Duration of warfarin therapy was positively attributed to satisfaction with treatment. 38, 40 Duration of low-molecular-weight heparin or unfractionated heparin therapy was associated with increased patient quality of life. 50 Injection treatments and compression devices are well tolerated by most patients. However, when given the choice, most patients would prefer injection treatment because of the discomfort associated with compression treatment 44 ( Table 8 ) .
affect reported values and preferences. For example, in the 2001 study by Man-Son-Hing et al, 26 enrollees in the Aspirin for Primary Prevention in the Low-risk Elderly (APPLE) pilot study would accept aspirin to gain a signifi cantly smaller reduction in fi rst-time stroke risk compared with those who did not enroll. This fi nding may indicate that individuals who enroll in trials may have higher acceptance for treatment than those who do not.
Results from a 2000 study by Man-Son-Hing et al 25 help to defend the claim that differing methods for preference and health state utility valuations may affect reported preferences. Of the 42 participants who rated preferences using two methods, 43% reported that they would base their decision on the results of the probability trade-off technique, and 17% would base their decision on the decision analysis. The remaining 40% had no preference between the two.
Results from a study by Bergus et al 24 suggest that methods used to relay information about risks and benefi ts of therapy may signifi cantly affect their reported preferences. Participants who received treatment benefi ts following risks were more likely to accept aspirin than those who received information in the opposite order. This may relate to the concept of loss aversion, which refers to the tendency for individuals to prefer avoiding loss in favor of gaining benefi ts. 55 The results of a study by Montori et al 2 illustrate that similar to other studies, previous experience with a given treatment affects the valuation of the outcomes or risks associated with that treatment ( Table 5 ) 
Results from Slot and Berge 30 indicate that compared with individuals who have not experienced a given health event, those who have may associate a higher utility to that event . This factor may be important to consider when eliciting health state valuations for outcomes associated with antithrombotic treatment. These studies also illustrate that other factors such as age, sex, and living situation affect willingness to accept or reject treatment options ( Table 6 ) 
One could infer from the results of Heyland et al 31 that many patients are extremely stroke averse (valuing avoiding stroke to a considerably greater extent than avoiding death). More likely, the results suggest that patients place a higher value on avoiding treat- of GI side effects, and 33% chance of bleeds (of which most would be minor bleeds). After reading identical introductory information about the use of aspirin, favorability ratings were similar between two groups. After being given more-detailed information (eg, risks, benefi ts), the study arm that received benefi ts before risks had signifi cantly reduced favorability ratings than those who received information in the opposite order (reduction of 10.9/100 vs a reduction of 5.2/100). Participants became less favorable to the intervention as they learned more about the risks (as rated on a scale of 0-100, where 100 is most favorable). Health risks associated with stroke were rated 78/100 in terms of the importance that this information plays on decision-making. Health risks associated with the intervention was rated 55/100, and health benefi ts associated with the intervention was rated 76.5/100. Major GI bleed MI Daily pill Given an increase in serious GI bleeds with aspirin of 2% over 5 y, the mean threshold risk reduction in MI required for patients to take aspirin using PTOT was 0.45% (0.31) and for stroke, 0.32% (0.28). Thus, the disutility patients placed on MI was on average more than four times that of bleeding, and for stroke, it was more than six times that of bleeding. Participant treatment thresholds elicited by the PTOT were consistently lower than using the decision analysis model. See Table 1 In the fi rst scenario, participants were asked to consider only stroke risks attributed to SK and tPA. Eighty-eight percent chose SK given stroke risk information (without being provided risks associated with death).
In the second scenario considering risk of death alone, 100% of participants chose tPA.
In the third scenario where participants were asked to consider stroke and death risk together, 66.7% chose tPA. Two-thirds of participants (2/1,000 patients) were unwilling to accept a small increased risk of stroke to avoid a 1% decreased risk of death on tPA. Thromboembolism prophylaxis All patients included in the study received both LMWH injections and foot pumps following their surgery. Almost 14% (13.9%) of patients found foot pumps to be painful, and 11.6% found injections to be painful. Seventy percent would agree to or were neutral about using the foot pump for 4 wk following surgery, whereas 86% of patients would agree to or were neutral about receiving injections. Fifty-one percent of patients found foot pumps comfortable, and 72% would agree to use them again if they were to have another joint replacement. Foot pumps are at least as well tolerated as dalteparin injections and are acceptable to the majority of patients.Participants also rated comfort level associated with each treatment along a 10-cm VAS, with 0 being most uncomfortable and 10 indicating most comfortable. Mean VAS score was 6.3
for the foot pump and 7.3 for the injections (statistically insignifi cant: P 5
.07). Injections were believed to be simpler than frequent INR monitoring on warfarin (which was very disruptive and painful).
One patient believed that bruising was an unacceptable side effect (but this patient had not previously taken warfarin). One percent of participants found that the injection treatment made them anxious, and another 1% found injections to be painful. Eleven percent of patients found EPC moderately to extremely inconvenient, 7% found it moderately to extremely uncomfortable, and 11% of patients removed the device because of inconvenience and discomfort.Postoperatively, 78% of the LMWH group and 74% of the EPC group preferred the method to which they had been randomized. LMWH may be more highly tolerated, but this fi nding was not statistically signifi cant. DVT prophylaxis (7 d following surgery) A total of 124 patients using the foot pump were asked about its acceptability. Five of 147 patients randomized to the foot pump stopped using it because they found it intolerable. Eleven percent found foot pumps quite comfortable, whereas 17% had diffi culty sleeping while using the pump.
In contrast, 8% found the pump to be very relaxing. treatment names (placebo, aspirin, and warfarin); the majority of these switches were to aspirin.
Discussion
We have carried out a systematic review of studies reporting patient values and preferences with regard to antithrombotic treatment. The results obtained through this review provide direction for guideline developers to base recommendations on patient values. In particular, this review highlights the apparently large variability in participant health state valuations and the factors, other than the impact of alternative management strategies on quantity and quality of life, that infl uence patient decisions.
A number of factors may explain the large variability in patient preferences both within and across studies. First, whether patients had experienced the treatments under consideration appeared to infl uence results. Typically, previous exposure with a given treatment was associated with a preference for continuing that same treatment. 12, 13, 45 Cognitive dissonance occurs when participants are inclined to modify their interpretation of information to ensure that it is consistent with their previous decision. 56 To reduce cognitive dissonance, participants who had previously been exposed to the treatments under consideration may be inclined to continue their treatment, even in the face of information suggesting that it is not the optimal choice. Patients who do not want to believe that they have been taking the wrong treatment may interpret the evidence presented so that it is consistent with their prior choice.
In addition, and perhaps most importantly, the differing methods used to elicit values and preferences may have resulted in differing apparent treatment preferences and health state valuations. Few studies attempted to determine whether methods such as probability trade-off, decision analysis, and differing methods for obtaining health state utilities would result in different choices. Indeed, in two studies, 20, 25 investigators found that methods used to elicit preferences signifi cantly affected treatment health state valuations and treatment thresholds.
The relatively small number of studies, their small sample sizes, their methodological limitations, and the large variability in their fi ndings limit the inferences that we can confi dently draw. We consider the following conclusions, however, as reasonably robust:
1. Values and preferences for antithrombotic treatment and for health states appear to vary appreciably among individuals. 2. Heterogeneity of results across studies-often diffi cult to explain-leaves appreciable uncertainty about average patient values.
Biases and Limitations Associated With Included Studies
There are a number of limitations associated with the included studies. Only three studies reported comprehension screening of potential participants, 3, 4, 12 and two used only the data from participants with consistent results. 6,31 Le Sage and colleagues 48 had research assistants walk through the survey with participants to ensure that the participants understood all the questions. It is possible that for those studies that did not pretest for comprehension, preferences elicited using methods such as time trade-off, probability trade-off, and standard gamble may have been compromised because of a lack of participant understanding. For example, Thomson et al 18 designed their study as a three-arm trial, one arm of which elicited patient preferences through the standard gamble method. After realizing that participants were having diffi culty understanding the standard gamble, they dropped that arm of the study.
Studies were also inconsistent in the descriptions of health states presented to participants in terms of both the number and the type of health states considered (eg, major bleed, major side effects, stroke). For example, Protheroe et al 15 grouped major and minor side effects together (not typical), whereas other studies did not consider minor side effects at all. As well, when describing the outcomes associated with stroke, some authors centered their descriptions on the physical effects, 30 whereas others considered additional aspects, such as the likelihood of becoming depressed or losing the ability to comprehend language. 21 Given the complexity of the treatment decision in this context, we do not consider studies to be biased if they neglected to consider rare or minor outcomes because including these may overwhelm participants and affect the validity of the outcomes.
The methodologic quality of the included studies is concerning, and most studies are compromised by some form of selection bias. For example, whether patients had previously experienced the condition or health events under consideration may have infl uenced their preference. Slot and Berge 30 found that those participants who had previously experienced a stroke tended to place a lower disutility on stroke than did those who had not experienced stroke events. Ideally, investigators would have recruited individuals recently given a diagnosis of the condition under study and who had not made a treatment decision. None of the included studies did.
In addition, participants' prior associations with the treatments under study may have affected willingness to accept specifi c treatment options. For example, Holbrook et al 10 found that 36% of participant treatment preferences changed once given the made the choices under investigation. Although prior experiences may result in a better understanding of the treatment under consideration, it may introduce factors other than preferences for the health states described in their responses (particularly cognitive dissonance). Second, in order to gain a better understanding of whether differing health state descriptions signifi cantly affect health state valuations, future research may test the impact of different descriptions on participant valuations. Ideally, standard descriptions of bleed and stroke outcomes would be developed and applied across studies. Finally, research should ensure that participants understand the preference elicitation exercise and explore factors that bear signifi cantly on patient decisions.
Our fi ndings also have implications for guideline development. The uncertainty and the variability in values and preferences among patients suggest that the present guideline panels should be circumspect in making strong recommendations. Strong recommendations should be restricted to situations in which the desirable consequences of an intervention substantially outweigh the undesirable consequences.
Study results suggest the following average values for the health states of interest: 3. Although there are troubling inconsistencies across studies, particularly in Man-Son-Hing et al, 14 a reasonable trade-off to assume between stroke and bleeds would be a ratio of disutility of net nonfatal stroke (thrombotic or hemorrhagic) to GI bleeds in the range of 2:1 to 3:1. 4. There is much less information about the relative disutility of myocardial infarction and bleeds, although it is clear that myocardial infarction has substantially less disutility than major stroke (and more than minor stroke). A reasonable trade-off to assume between myocardial infarction and bleeds would be 1:1 to 2:1. 5. The only conclusion that one can make regarding the relative disutility of major bleed vs DVT is that it varies widely among patients. 6. Patients are unwilling to accept a small increase in risk of death to avoid the postthrombotic syndrome. 5, 23 Study results suggest the following preferences for the antithrombotic interventions: The present study has several limitations. Given the large number of abstracts that were selected for review (N 5 17,086), it was not feasible to seek out articles that could not be obtained online. Therefore, this study comprises only articles that could be accessed through the electronic library at McMaster University. Eight articles that we deemed potentially relevant were special ordered; two proved eligible. It is possible that we were unable to capture every eligible study in this review, and we expect that authors may come forward with additional studies to be included in an update of this review. Although we attempted to locate unpublished studies by reviewing the gray literature and contacting experts in the fi eld (which did produce two additional articles), this review risks publication bias. 57 Our fi ndings have a number of implications for future studies eliciting patient values and preferences. First, investigators should elicit values and preferences from participants who have not previously
